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Abstract. A group Al diabetic received a pancreas-spleen transplant from a group 0 
donor. Severe immune hemolysis due to anti-A ensued, requiring graft splenectomy. The 
transplanted spleen can be a potent source of blood group antibody. 
Introduction 
The temporary appearance of anti-A or 
anti-B isohemagglutinins in non-group 0 pa-
tients .receiving a transplanted organ from a 
group 0 donor has been observed following 
transplantation oflung [1], kidney [2-4], and 
liver [5]. We have investigated a case of anti-
A formation and severe hemolysis following 
pancreas-spleen transplantation from a 
group 0 donor into a group A recipient. 
Materials and Methods 
The patient's serum was tested for the presence of 
ABO antibody activity at room temperature (RT), 37 "C, 
and by antiglobulin testing with freshly drawn AI' A2, B-
and 0 red blood cells (RBC). The direct antiglobulin 
tests, 56'C heat eluates, and dithiothreitol (DTT) treat-
ment of the serum were performed by established pro-
cedures [6]. Agglutination reactions were scored as de-
scribed by [ssitt and [ssitt [7]. 
Case History and Results 
The patient was a group Al 35-year-old 
white male admitted for pancreas transplan-
tation. He had been a diabetic requiring 
insulin injections since the age of 5. In addi-
tion to neuropathy and retinopathy, in 1981 
he developed renal failure and required dial-
ysis. In December 1982 he received a suc-
cessful cadaveric kidney transplant with cy-
closporine immunosuppression. Despite a 
strict insulin regimen, his blood glucose 
ranged between 44 and 425 mg/dl, without 
good control. On March 6, 1983, he received 
a cadaveric pancreas transplant from a 
group 0 donor. The donor pancreas, spleen, 
and a segment of duodenum were trans-
planted en bloc, with the duodenum anasto-
mosed to the recipient's jejunum [8]. The 
recipient's pancreas and spleen were left in 
situ. The estimated blood loss during surgery 
was about 100 ml. No blood products were 
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transfused. A course of corticosteroids was 
added to the ongoing cyclosporine immuno-
suppreSSIOn. 
The patient's clinical course is illustrated 
in figure 1. The hemoglobin and hematocrit 
on the day of surgery were 13.8 g/dl and 
41.3%, but fell steadily over the first 5 post-
operative days to 7.4 g/dl and 21%, respec-
tively. with no evidence of hemorrhage. At 
this time, the haptoglobin was 35 mg/dl and 
reticulocyte count 5.5%. Direct and indirect 
serum bilirubin were 1.0 and 2.9 mg/dl, re-
spectively. The urine was positive for uro-
bilinogen. The platelet count declined from 
a preoperative level of 232 x 109/1 to 
137 x 109/1 by the 7th postoperative day. 
Prior to surgery, the direct and indirect 
antiglobulin tests were negative. Because of 
the falling hematocrit, blood was ordered 
crossmatched for transfusion 4 days after 
surgery. Group A units were found to be 
incompatible at RT (1+). 3TC (1+) and by 
antiglobulin testing (3+). The direct anti-
globulin test (DAT) was positive (broad 
spectrum 4+, anti-IgG 3+, anticomplement 
Fig. I. Serologic and hematologic 
course after transplantation or group 
o spleen to group AI recipient. 
1+). Antibody eluted from the patient's RBC 
agglutinated AI cells (4+) and A2 cells (1+), 
but not group 0 cells. From days 4-6 post-
operatively, serum anti-A agglutination 
scores against group AI cells at RT, 37'C, 
and at the antiglobulin phase, rose from 10, 
5, and 50 to 10, 10, and 62, respectively. 
DTT treatment of the patient's serum re-
duced the scores only slightly. No reactivity 
was observed when testing the patient's se-
rum against A2 cells. After absorption of the 
serum with AI cells, an eluate from these 
cells reacted 1+ with AI cells. very weakly 
with A2 and B cells, and was negative with 
group 0 cells. On day 6, the transplanted 
spleen was removed. The spleen weighed 
190 g (normal150 g); histopathology showed 
prominent immunoblastic proliferation and 
red pulp congestion, consistent with im-
mune stimulation and hemolysis. During 
and after splenectomy the patient received a 
total of7 units of washed group 0 RBC. 
After splenectomy the anti-A scores fell 
steadily but the antibody was still detectable 
7.5 weeks later. The patient's hematocrit 
Anti-A from Transplanted Spleen 
stabilized and his blood glucose became nor-
mal. All evidence of anti-A disappeared by 3 
months, and was also absent I year later. 
Discussion 
This group AI patient had severe immune 
hemolysis due to anti-A after transplanta-
tion of a group 0 spleen with a pancreatic 
graft. The antibody was of AI specificity, 
though a trace of anti-AB activity was de-
tectable in the serum. While it is likely that 
plasma containing anti-A was administered 
passively along with the transplanted or-
gans, the following evidence indicates that 
the transplanted spleen was actively produc-
ing anti-A isohemagglutinins: (1) The vol-
ume of plasma in the transplant was un-
doubtedly small and would be diluted sub-
stantially in the recipient's plasma. (2) 
Plasma anti-A levels rose significantly be-
tween postoperative days 4 and 6, indicating 
synthesis of new antibody. (3) The DA T also 
increased in strength during this period of 
time. (4) Splenectomy of the graft reversed 
this process. (5) The spleen showed evidence 
of immune stimulation on histological ex-
amination. We conclude that the spleen, a 
large lymphoid organ, produced a marked 
graft-versus-host anti-A isohemagglutinin 
response when challenged by the transplant 
recipient's AI antigen. 
Inclusion of the spleen in total pancreatic 
transplantation offers several possible ad-
vantages [8]. The splenic vessels supply 
much of the pancreatic venous drainage, and 
preserving them in toto may help prevent 
splenic vein thrombosis, a common problem 
in this procedure. Intraoperative trauma to 
the pancreas may be lessened by a wider en 
bloc dissection. Experimental evidence sug-
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gests a protective effect of splenic transplan-
tation on survival of other concomitant or-
gan grafts, including the pancreas [9]. How-
ever, as shown in our case, the donor should 
have the same ABO group as the recipient, an 
important consideration in future trans-
plants of this kind. 
A case similar to ours was reported in 
1964 [10]. In an experimental protocol at-
tempting transfer of tumor immunity to pa-
tients with carcinoma, 1 group A recipient 
received a group 0 spleen. Severe hemolysis 
ensued. While being prepared for splenecto-
my, the patient aspirated and died. The 
pathogenesis of this hemolysis was un-
doubtedly the same as in our case. 
Anti-recipient ABO antibody has occa-
sionally been reported after other instances 
where a group 0 organ was transplanted to a 
group A recipient. Beck et a1. [1] noted a lung 
transplant patient in which a positive direct 
antiglobulin test occurred. 3 O-to-A kidney 
transplants have been followed by mild to 
moderate hemolysis due to anti-A, the anti-
body persisting for up to 60 days after sur-
gery [2-4]. We have studied 8 cases of mod-
erate to severe hemolysis due to anti-re-
cipient ABO antibody after unmatched liver 
transplantation, including recipients who 
were group Band AB as well as group A [5]. 
In addition to the spleen, the largest lym-
phoid organ, these other grafts apparently 
also can contain enough lymphocytes to 
form clinically significant antibodies to host 
red cells, even in the setting ofposttransplant 
. . ImmunosuppreSSIon. 
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